Phase 2 Breast Cancer Trial, Recruiting NCT06462092 Sponsor: Guangzhou Medical University Condition: Breast Cancer
Back to Breast Cancer

Phase 2 Breast Cancer Trial, Recruiting

NCT06462092
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with breast cancer that has been confirmed by laboratory testing to be HER2-negative (a specific tumour type identified through tissue testing)
  • People whose cancer has spread to the membranes surrounding the brain and spinal cord (called leptomeningeal metastases), confirmed either through a spinal fluid test or through scans combined with symptoms
  • People aged 18 or older

Who may not be able to join:

  • People whose blood test results show that the bone marrow, liver, or other organs are not functioning well enough to safely participate (specific blood count and liver function thresholds apply — confirm with trial site)
  • People who have a known allergy to the study drugs or their ingredients
  • People with a weakened immune system, such as those who are HIV-positive or have another immune deficiency condition
  • People with other serious ongoing health conditions that could affect safe participation in the trial
  • People who are pregnant or breastfeeding
  • Women of childbearing age who are unwilling or unable to use effective contraception during the trial
  • People who, for any other reason, the trial doctor considers unsuitable for participation

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Zhenyu Pan, Huizhou Hospital of Guangzhou Medical University

Phone: +8618718178286

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Guangzhou Medical University
Registry
ClinicalTrials.gov
Start date
1 January 2026
Est. completion
15 January 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Maximal tolerated dose

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov